

Curriculum Vitae Michael Hertl

Personal Data

Title	Prof. Dr. med.
First name	Michael
Name	Hertl
Current position	Professor and Chairman (C4, permanent)
Current institution(s)/site(s), country	Department of Dermatology and Allergology, University of Marburg (UMR), Germany
Identifiers/ORCID	0000-0002-5494-2461

Selection of peer-reviewed research articles:

1. Didona D, Scarsella L, Hudemann C, *et int*, **Hertl M**. Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris. *J Invest Dermatol*. 2024 Feb;144(2):263-272.e8. doi: 10.1016/j.jid.2023.07.025.
2. Holstein J, Solimani F, Baum C, *et int*, **Hertl M**, *et int*, Möbs C. Immunophenotyping in pemphigus reveals a TH17/TFH17 cell dominated immune response promoting desmoglein1/3-specific autoantibody production. *J Allergy Clin Immunol*. 2021 Jun;147(6):2358-2369. doi: 10.1016/j.jaci.2020.11.008.
3. Schmidt T, Solimani F, Pollmann R, *et int*, **Hertl M**. TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. *J Allergy Clin Immunol*. 2018 Aug;142(2):669-672.e7. doi: 10.1016/j.jaci.2018.02.044.
4. Eming R, Hennerici T, Bäcklund J, *et int*, **Hertl M**. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells. *J Immunol*. 2014 Nov 1;193(9):4391-9. doi: 10.4049/jimmunol.1401081.
5. Rafei, D., Müller, R., Norito, I., *et int*, **Hertl, M.**[#], Eming, R.[#] IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. *Am. J. Pathol*. 2011 Feb;178(2):718-23. doi: 10.1016/j.ajpath.2010.10.016.
6. Eming R, Nagel A, Wolff-Franke S, *et int*, **Hertl M**. Rituximab exerts a dual effect in pemphigus vulgaris. *J Invest Dermatol*. 2008 Dec;128(12):2850-8. doi: 10.1038/jid.2008.172.
7. Joly P, Mouquet H, Roujeau JC, *et int*, **Hertl M**, Musette P. A single cycle of rituximab for the treatment of severe pemphigus. *N. Engl. J. Med*. 2007 Aug 9;357(6):545-52. doi: 10.1056/NEJMoa067752.
8. Veldman CM, Gebhard KL, Uter W, *et int*, **Hertl M**. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. *J Immunol*. 2004 Mar 15;172(6):3883-92. doi: 10.4049/jimmunol.172.6.3883.
9. Veldman C, Höhne A., Dieckmann D., *et int*, **Hertl M.** Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. *J. Immunol*. 172:6468-75, corr *J. Immunol*. 2004 May 15;172(10):6468-75. doi: 10.4049/jimmunol.172.10.6468.
10. Büdinger, L., Borradori, L., Yee, C., *et int*, **Hertl, M**. Identification and Characterization of Autoreactive T Cell Responses to Bullous Pemphigoid Antigen 2 in Patients and Healthy Controls. *J. Clin. Invest*. 1998 Dec 15;102(12):2082-9. doi: 10.1172/JCI3335.